With a history of serving executive roles for senior-level biopharmaceutical research and development firms, David Palling most recently served as Senior Vice President for Chromocell Corporation’s therapeutics division. He maintained responsibility for the growth of the division while providing leadership in the early discovery and pre-clinical developmental stages of development. To further the company, David Palling established a medicinal chemistry group that supplemented the firm's existing biology expertise. He also developed new strategies and implemented projects for pain, respiratory, and renal disease areas. In addition, Dr. Palling took on responsibility for operations relating to the IT and HR departments and served on the executive management committee. Previously, David Palling spent one year as an independent consultant, helping start-up companies with business plans, technology assessments, and fundraising. Prior to that, he spent seven years with Amicus Therapeutics, Inc., a biopharmaceutical company in Cranbury, New Jersey, which he joined at the company’s founding. David Palling took on a great deal of responsibility for budget, facilities, staffing, and information technology. He also established the firm’s scientific and medical advisory boards, managed its Series B financing, and organized scientific presentations to foster collaborations. Later, David Palling assisted with clinical development and regulatory affairs; manufacturing, quality, and technical operations; and IND-enabling studies. David Palling also held positions with other pharmaceutical companies, including Johnson & Johnson, Inc., J & J Pharmaceutical Research and Development, and Hoffmann-La Roche Inc. Prior to entering the workforce, he attended the University of London, where he earned a Bachelor of Science in Chemistry and a Doctorate in Organic Chemistry. Mr. Palling then studied at Brandeis University in Massachusetts, conducting research in physical organic chemistry, analytical chemistry, and solution kinetics.